Skip to content
Search

Latest Stories

Cigarette maker Philip Morris clinches £1bn takeover of inhaler maker Vectura; RPS, health organisations 'deeply concerned'

US cigarette firm Philip Morris International (PMI) on Thursday clinched a controversial takeover of British breathing inhaler manufacturer Vectura, despite fierce opposition from health campaigners and medical groups.

The Marlboro-maker agreed in July to pay £1.0 billion as part of a broader push into healthcare.


PMI on Thursday (September 16) said it had since won the necessary support from investors and secured regulatory approvals.

The acquisition is part of PMI's plans to expand beyond tobacco and nicotine and into a broader healthcare company.

"We have reached an important milestone in our acquisition of Vectura," PMI chief executive Jacek Olczak said in a statement.

The group has identified respiratory drug delivery as a key focus, under broader plans to generate at least $1.0 billion in annual net revenues from nicotine-free products by 2025.

"We are very excited about the critical role Vectura will play in our Beyond Nicotine strategy and look forward to working with Vectura's scientists and providing them with the resources and expertise to grow their business to help us achieve our goal," added Olczak.

Since 2008, the cigarette giant has invested more than $8.0 billion in smoke-free products, such as vaping, which it says is less harmful than smoking.

However, the Vectura takeover has faced heavy criticism from charities and medical groups.

The healthcare community believes that the announced takeover will legitimise tobacco industry participation within health debates and provide a greater platform from which to deploy similar tactics in support of tobacco industry interests.

Fierce opposition

More than 20 organisations, including anti-smoking charities and public health groups, together wrote to Vectura management urging it to reconsider the takeover on ethical and practical grounds.

Health organisations and charities have also written to pharmacy minister Jo Churchill to express deep concerns about the takeover of Vectura.

Sarah Woolnough, chief executive of both Asthma UK and the British Lung Foundation, accused Vectura of seeking a quick profit.

"Vectura has sold out millions of people with lung disease, and instead prioritised short-term financial gain over the long-term viability of Vectura as a business," she said.

"Vectura is now owned by a tobacco company, and this could cause considerable problems, such as the firm being excluded from research and clinical networks."

She added that it "creates perverse incentives for Philip Morris International to sell more of its harmful products so they might then profit again through treating smoking-related diseases".

RPS deeply concerned 

President of Royal Pharmaceutical Society Claire Anderson, who is a signatory of the letter to Churchill, said: “We are deeply concerned about today’s takeover of Vectura by Philip Morris International.

“This takeover not only creates an ethical dilemma for healthcare professionals but poses a threat of the tobacco industry participating in health debates and benefitting from this involvement.

“Therefore, we have signed the letter urging the Government to enforce FCTC Article 5.3, and to make any guidance given to departments dealing with Vectura public.”

More For You

Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Independent Prescribing: Government aims to complete pathfinder programme evaluation by autumn 2025

Pharmacist prescribers at 210 ‘pathfinder’ sites were allowed to trial prescribing models within integrated primary care services.

Photo credit: gettyimages

Independent prescribing: Pathfinder programme evaluation to be completed by autumn, says Kinnock

Health minister Stephen Kinnock has revealed that the evaluation of the Community Pharmacy Independent Prescribing Pathfinder Programme could be completed by Autumn 2025.

Kinnock was responding to a question from James Naish, Labour MP for Rushcliffe, who asked what steps the minister was taking to ensure continued support for the Pathfinder Programme and independent prescribing to maximise direct prescribing capacity in England.

Keep ReadingShow less
Free morning-after pill at pharmacies to end postcode lottery for patients

Pharmacy technicians will be allowed to supply of drospirenone for contraception under PGD,

gettyimages

Pharmacy contract: Free morning-after pill to be available at pharmacies soon

The UK government has announced that, for the first time ever, the ‘morning-after pill’ or emergency contraceptive pill will be available free of charge at pharmacies on the NHS, ending the postcode lottery women face in accessing the medicine and reducing inequalities.

The Department of Health and Social Care (DHSC) has confirmed a record £3.073 billion funding package for community pharmacies in 2025/26, alongside an additional £215 million to sustain Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Royal College status: The PDA calls for ‘meaningful and collaborative dialogue’

The profession’s success will depend on collaboration across all sectors, says PDA.

gettyimages

Royal College vote: Less than 7% of GB pharmacists in favour, says PDA

The Pharmacists’ Defence Association (PDA) has criticised the Royal Pharmaceutical Society (RPS) for moving too quickly to a ballot on its proposed transition to a Royal College, arguing that it resulted in low participation from pharmacists in Great Britain.

Announcing the results of the special resolution vote, the RPS said that the outcome was a “clear mandate” in favour of the transformative change.

Keep ReadingShow less